PMID- 28178685
OWN - NLM
STAT- MEDLINE
DCOM- 20180406
LR  - 20220410
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 26
DP  - 2017 Jun 27
TI  - Overwhelming rapid metabolic and structural response to apatinib in radioiodine 
      refractory differentiated thyroid cancer.
PG  - 42252-42261
LID - 10.18632/oncotarget.15036 [doi]
AB  - Currently, patients with radioiodine refractory differentiated thyroid cancer 
      (RAIR-DTC) have limited treatment options. In this study, we aimed to assess the 
      short-term efficacy and safety of apatinib in RAIR-DTC. Ten adult patients were 
      prospectively enrolled to receive oral apatinib (750 mg q.d). The primary 
      endpoints were change in serum thyroglobulin (Tg) concentration, disease control 
      rate (DCR) and objective response rate (ORR) based on RECIST 1.1 criteria. The 
      secondary endpoints included change in glucose metabolism, evaluated by maximum 
      standard uptake value (SUVmax), and safety. As early as 2 weeks after apatinib 
      treatment, the serum Tg concentration decreased by 21.0% in 8 patients available 
      for detection without interference, and a further sharp decline by 81.4% compared 
      with the baseline level occurred at 8 weeks post-treatment. The DCR and ORR were 
      100% (10/10) and 90% (9/10), respectively. The sum of tumor diameter shrank to 
      22.8+/-8.1 mm from 38.8+/-15.7 mm (P=0.001). Moreover, a significant decrease in 
      SUVmax was observed from 6.53+/-5.14 to 2.56+/-1.67 and 2.45+/-1.48 at 4-week and 
      8-week time-points after treatment (P=0.032 and 0.020), respectively. The common 
      grade 3 adverse events (AEs) included hand-foot-skin reaction (50%), hypertension 
      (30%), and hypocalcemia (20%). No severe AE related to apatinib was observed 
      during treatment. Hence, apatinib seems to be a promising therapeutic option for 
      RAIR-DTC patients. Apart from RECIST 1.1 criteria, the biochemical marker (Tg) 
      and glucose metabolism index (SUVmax) could be adopted in assessing the early 
      response to TKI in RAIR-DTC.
FAU - Lin, Yansong
AU  - Lin Y
AD  - Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing 
      100730, China.
FAU - Wang, Chen
AU  - Wang C
AD  - Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing 
      100730, China.
FAU - Gao, Wen
AU  - Gao W
AD  - Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao 
      266555, China.
FAU - Cui, Ruixue
AU  - Cui R
AD  - Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing 
      100730, China.
FAU - Liang, Jun
AU  - Liang J
AD  - Department of Oncology, Peking University International Hospital, Beijing 102206, 
      China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Iodine Radioisotopes)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyridines)
RN  - 5S371K6132 (apatinib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/adverse effects/pharmacokinetics/*therapeutic use
MH  - Female
MH  - Humans
MH  - Iodine Radioisotopes/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Positron Emission Tomography Computed Tomography
MH  - Protein Kinase Inhibitors/adverse effects/pharmacokinetics/*therapeutic use
MH  - Pyridines/adverse effects/pharmacokinetics/*therapeutic use
MH  - Retreatment
MH  - Thyroid Neoplasms/diagnostic imaging/*drug therapy/*pathology
MH  - Tomography, X-Ray Computed
MH  - Treatment Outcome
PMC - PMC5522064
OTO - NOTNLM
OT  - apatinib
OT  - maximum standard uptake value
OT  - radioiodine refractory differentiated thyroid cancer
OT  - safety
OT  - thyroglobulin
COIS- CONFLICTS OF INTEREST The authors have no conflicts of interest to declare.
EDAT- 2017/02/09 06:00
MHDA- 2018/04/07 06:00
PMCR- 2017/06/27
CRDT- 2017/02/09 06:00
PHST- 2016/09/26 00:00 [received]
PHST- 2017/01/08 00:00 [accepted]
PHST- 2017/02/09 06:00 [pubmed]
PHST- 2018/04/07 06:00 [medline]
PHST- 2017/02/09 06:00 [entrez]
PHST- 2017/06/27 00:00 [pmc-release]
AID - 15036 [pii]
AID - 10.18632/oncotarget.15036 [doi]
PST - ppublish
SO  - Oncotarget. 2017 Jun 27;8(26):42252-42261. doi: 10.18632/oncotarget.15036.